Stock 4746 FORMOSA LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Formosa Laboratories, Inc.

Equities

4746

TW0004746003

End-of-day quote Taiwan S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
101 TWD -0.98% Intraday chart for Formosa Laboratories, Inc. +2.33% -0.98%
Mar. 12 Formosa Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 12 Formosa Laboratories, Inc. Approves Dividend Distribution for Full Year Ended December 31, 2023 CI

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
FORMOSA LABORATORIES, INC. Stock Formosa Laboratories, Inc.
-0.98% 372M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 704B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 577B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 348B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 327B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.36% 288B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 234B
B+
NOVARTIS AG Stock Novartis AG
+4.93% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
A+
AMGEN INC. Stock Amgen Inc.
-3.69% 147B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4746 Stock
  4. Ratings Formosa Laboratories, Inc.